Company Active LTD

Company profile

Machine Medicine Technologies Limited

Machine Medicine - Motor assessment made simple and scalable

We offer new levels of precision, reliability and objectivity in tracking motor dysfunction in patients with movement disorders.

CRN
10787420
Founded
2017
Age
9

Overview

Legal name
MACHINE MEDICINE TECHNOLOGIES LIMITED
Region
London
Registered address
3 DARTLE COURT
DICKENS ESTATE
LONDON
UNITED KINGDOM
SE16 4PX
Insolvency history
No

Latest accounts

Financial period: 1 Nov 2024 to 31 Oct 2025

FILLETEDACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
9

Company events

Reference milestones and recent Companies House filing stream events.

7 events
31 Jul
2027

Accounts due

Accounts Due

Next accounts due date

21 Mar
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

07 Mar
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Oct
2025

Accounts filed

Accounts

Last accounts made up date

26 Nov
2024

Accounts With Accounts Type Total Exemption Full

Accounts Analysed

AA | Transaction MzQ0NDkwMjI4NmFkaXF6a2N4

Published 26 Nov 2024 10:13

19 Nov
2024

Capital Allotment Shares

Capital

SH01 | Transaction MzQ0NDA4OTE5M2FkaXF6a2N4

Published 19 Nov 2024 10:13

24 May
2017

Incorporated

Inception

Company registered at Companies House

Public funding

3 awards
First funded
2019
Funded years
2019, 2020, 2022
Age at first award
1 years

Projects

2022 Collaborative R&D Lead participant

GEMINI-OS : platform informatics for data-driven neuromodulation

1 Dec 2022 to 30 Nov 2025

Awarded
£949,350
Total cost £1,356,214

Deep Brain Stimulation (DBS) is an established treatment for advanced Parkinson's disease (PD) and tremor which may significantly improve their quality of life. PD is a progressive disease for which there are symptomatic treatments but no cure. In the advanced stages, medications can fail to control symptoms and commonly cause movement and non-movement re...

2020 Feasibility Studies Lead participant

Project Elongation Support for KELVIN: Computer Vision Based Biomarkers of Motor Dysfunction in Parkinson's Disease

1 Jun 2020 to 30 Nov 2020

Awarded
£186,149
Total cost £186,149

no public description

2019 Collaborative R&D Lead participant

KELVIN: Computer Vision Based Biomarkers of Motor Dysfunction in Parkinson’s Disease

1 Apr 2019 to 31 Mar 2022

Awarded
£424,939
Total cost £607,056

Diseases of the CNS (Central Nervous System) often affect mobility and behaviour. However, historically it has been extremely difficult to measure mobility and behaviour objectively. Instead, researchers have relied upon subjective and unreliable measures such as patient questionnaires and clinical scores. Not only do these tools yield poor quality data, ...

Product types

Collaborative R&D Feasibility Studies